# BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

> **NCT05935098** · PHASE1 · TERMINATED · sponsor: **BeiGene** · enrollment: 99 (actual)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor
- Solid Tumor

## Interventions

- **DRUG:** BGB-A3055
- **DRUG:** Tislelizumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT05935098
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-21
- **Primary completion:** 2026-01-27
- **Final completion:** 2026-01-27
- **Target enrollment:** 99 (ACTUAL)
- **Why stopped:** This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the CCR8 program.
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05935098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05935098, "BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05935098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*